NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its $471 million acquisition of German diagnostics firm Brahms, the firm said today.

Thermo Fisher initially announced the deal in early September. The acquisition will complement its immunoassay test portfolio and expand its reagent manufacturing capabilities in Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.